Subscribe To
1 under-the-radar stock that could triple by 2030
Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading ...
November 4, 2023, 7:30 am
Taysha gene therapies: tsha-102's potential is a 'buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead ...
November 3, 2023, 7:41 pm
Update: korro bio and frequency therapeutics announce closing of merger and private placement of $117 million
Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...
November 3, 2023, 7:31 pm
Cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy ...
November 3, 2023, 6:57 pm
Korro bio and frequency therapeutics announce closing of merger and private placement of $117 million
Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fu...
November 3, 2023, 4:19 pm
Argentine presidential candidate sergio massa proposes bitcoin mining using ‘dead cow’ gas
Presidential candidate in Argentina, Sergio Massa, has put forth a contentious proposal to mine Bitcoin...
November 3, 2023, 9:59 am
Should you still buy the nasdaq's best-performing october stocks?
Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesit...
November 3, 2023, 5:20 am
Kbwp: this p&c insurance etf is on the verge of breaking through
KBWP is one of the niche ETFs on my short list of candidates to own as the equity market gradually show...
November 3, 2023, 12:14 am
Regenxbio: biotech to watch with 2 possible accelerated approval pathways
Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead ...
November 2, 2023, 5:33 pm
4 in 10 small business owners say job openings are hard to fill. here are 3 ways to attract talent
Also, being open to remote work expands your applicant pool. You don’t have to be limited to candidate...
November 2, 2023, 11:14 am
Tourmaline bio: ted and ascvd targeting with differentiated il-6
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye dise...
November 1, 2023, 2:09 pm
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIR...
November 1, 2023, 11:30 am
Cardiol therapeutics reaches new milestone in phase ii study for recurrent pericarditis
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-...
November 1, 2023, 8:41 am
Aptevo to present at bio-europe conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing nov...
November 1, 2023, 7:45 am
Where will the next fintech hub be in 2024?
Over the last decade, the global fintech environment has grown dramatically, with innovation hotspots like Silicon Valley, London, and Singapore emerg...
October 31, 2023, 12:06 pm
Omega therapeutics presents new preclinical data demonstrating pre-transcriptional modulation of multiple cxcl genes by a single epigenomic controller
Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition ...
October 31, 2023, 11:00 am
Argentina’s pro-bitcoin javier milei heads to run-off election against sergio massa
Argentina will choose between current Finance Minister Sergio Massa and pro-bitcoin candidate Javier Mi...
October 30, 2023, 4:59 pm
Novartis says drug candidate is successful in rare kidney disease trial
Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney d...
October 30, 2023, 3:42 am
Cassava sciences: my bullish take on biomarkers and ctad data
Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidat...
October 30, 2023, 3:30 am
Novo nordisk just consolidated its grip on yet another market. is it a buy?
Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could als...
October 29, 2023, 9:30 am